Skip to main content
Signal8

LEMAITRE VASCULAR INC (LMAT)

Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Instruments & Supplies

LeMaitre Vascular, Inc. logo

LeMaitre Vascular, Inc.

NASDAQ:LMATHealthcare
-5.08%$80.94
AH$80.94+0.00%vs close
Mkt Cap$1.85B
Float21.2M
O/S22.87M
Vol
$ Vol
RVOL
Inst Own100.9%
SI8.4%
Earnings
Div Yield1.17%
Dilution
Phase Distribution
8 lead-sponsored trials·5 active·2 completed
Phase 21
Not applicable7
(1 more as collaborator)
Status Overview
Recruiting2
Active, not recruiting3
Completed2
Stopped1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 2
    Terminated

    Study to Evaluate the Performance and Safety of Expedial and Compare it to Expanded Polytetrafluoroethylene (ePTFE) Vascular Access Grafts

    Expedial Vascular Access Graft

    End Stage Renal Disease

    Enrollment
    172
    Start
    Mar 2004
    Primary Completion
    -
    Completion
    Nov 2006
    NCT00131872
  • Not applicable
    Active, not recruiting

    Evaluate Safety and Effectiveness of XenoSure® Biological Patch in the Application of Peripheral Vascular Repair

    Implant the XenoSure patch, Repair/reconstruction of the diseased vessel

    Vascular Diseases

    Enrollment
    144
    Start
    Jul 2017
    Primary Completion
    Nov 2025est.
    Completion
    Nov 2025est.
    NCT03173703
  • Not applicable
    Completed

    Evaluate Safety and Effectiveness of XenoSure Biological Patch in the Application of Cardiac Repair

    Open heart surgery to address the heart disease, Close the defects with XenoSure Patch

    Heart Diseases

    Enrollment
    142
    Start
    Aug 2017
    Primary Completion
    Nov 2020
    Completion
    Feb 2024
    NCT03176225
  • Observational
    Active, not recruiting

    Prospective and Non-randomized Registry of CardioCel 3D

    CardioCel implantation

    Intracardiac and Septal Defects, Valve and Anulus Repair +3

    Enrollment
    200
    Start
    Aug 2020
    Primary Completion
    Nov 2025est.
    Completion
    Mar 2026est.
    NCT04175327
  • Observational
    Completed

    LeMaitre LifeSpan® ePTFE Vascular Graft Retrospective Registry

    AV Access, PVP

    Diseased or Occluded Blood Vessels, Arteriovenous Shunting for Blood Access

    Enrollment
    153
    Start
    Nov 2020
    Primary Completion
    Nov 2023
    Completion
    Nov 2023
    NCT04620889
  • Observational
    Active, not recruiting

    Post-Market Registry in Europe and US for the Use of VascuCelTM

    great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing

    Great Vessel Reconstruction, Peripheral Vessel Reconstruction +1

    Enrollment
    100
    Start
    Jun 2023
    Primary Completion
    Oct 2025est.
    Completion
    Sep 2026est.
    NCT04906824
  • Not applicable
    Recruiting

    A PMCF Study to Confirm the Performance and Safety of the LeMaitre® TufTex Single Lumen Embolectomy Catheter

    TufTex Single Lumen Embolectomy Catheter

    Arterial Thromboembolism

    Enrollment
    112
    Start
    Jan 2022
    Primary Completion
    Jun 2027est.
    Completion
    Jun 2027est.
    NCT05386277
  • Not applicable
    Recruiting

    A PMCF Study Confirm the Performance and Safety of the TufTex Over-the-Wire (OTW) Embolectomy Catheters

    TufTex Over-the-Wire Embolectomy Catheter

    Thrombus, Embolus +1

    Enrollment
    112
    Start
    Jan 2023
    Primary Completion
    Jun 2027est.
    Completion
    Jun 2027est.
    NCT05386342